Antiviral activity of RhoA-derived peptides against respiratory syncytial virus is dependent on formation of peptide dimers

被引:14
作者
Budge, PJ
Lebowitz, J
Graham, BS
机构
[1] NIAID, Vaccine Res Ctr, NIH, Bethesda, MD 20892 USA
[2] NIH, Div Bioengn & Phys Sci, Off Res Serv, Off Director, Bethesda, MD 20892 USA
[3] Vanderbilt Univ, Med Ctr, Dept Microbiol & Immunol, Nashville, TN 37232 USA
关键词
D O I
10.1128/AAC.47.11.3470-3477.2003
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
A synthetic peptide containing amino acids 77 to 95 of the intracellular GTPase RhoA has previously been shown to inhibit replication of respiratory syncytial virus (RSV) in cultured cells. We show that residues 80 to 90 of RhoA are sufficient for this activity and that the cysteine residue at position 83 is critical. Further studies with an optimal peptide sequence containing amino acids 80 to 94 of RhoA revealed that the antiviral potency of the peptide is dependent on the oxidation of cysteine 83. Size-exclusion chromatography and sedimentation equilibrium studies of the peptide comprising residues 80 to 94 revealed that it is capable of forming aggregates in both reduced and oxidized states. A peptide (83A) in which the cysteine residue is replaced by an alanine does not form dimers or higher-order aggregates and did not inhibit RSV replication at any concentration tested. These data indicate that formation of peptide multimers is necessary for the antiviral activities of RhoA-derived peptides and suggest that the observed antiviral activities of these peptides may be unrelated to the biological functions of their parent molecule.
引用
收藏
页码:3470 / 3477
页数:8
相关论文
共 30 条
  • [21] A RhoA-derived peptide inhibits syncytium formation induced by respiratory syncytial virus and parainfluenza virus type 3
    Pastey, MK
    Gower, TL
    Spearman, PW
    Crowe, JE
    Graham, BS
    [J]. NATURE MEDICINE, 2000, 6 (01) : 35 - 40
  • [22] An update on respiratory syncytial virus antiviral agents
    Prince, GA
    [J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2001, 10 (02) : 297 - 308
  • [23] Structure at 1.65 angstrom of RhoA and its GTPase-activating protein in complex with a transition-state analogue
    Rittinger, K
    Walker, PA
    Eccleston, JF
    Smerdon, SJ
    Gamblin, SJ
    [J]. NATURE, 1997, 389 (6652) : 758 - 762
  • [24] Membrane fusion machines of paramyxoviruses: capture of intermediates of fusion
    Russell, CJ
    Jardetzky, TS
    Lamb, RA
    [J]. EMBO JOURNAL, 2001, 20 (15) : 4024 - 4034
  • [25] An open conformation of switch I revealed by the crystal structure of a Mg2+-free form of RHOA complexed with GDP -: Implications for the GDP/GTP exchange mechanism
    Shimizu, T
    Ihara, K
    Maesaki, R
    Kuroda, S
    Kaibuchi, K
    Hakoshima, T
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (24) : 18311 - 18317
  • [26] DISULFIDE BOND FORMATION IN PEPTIDES BY DIMETHYL-SULFOXIDE - SCOPE AND APPLICATIONS
    TAM, JP
    WU, CR
    LIU, W
    ZHANG, JW
    [J]. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1991, 113 (17) : 6657 - 6662
  • [27] Functional analysis of recombinant respiratory syncytial virus deletion mutants lacking the small hydrophobic and/or attachment glycoprotein gene
    Techaarpornkul, S
    Barretto, N
    Peeples, ME
    [J]. JOURNAL OF VIROLOGY, 2001, 75 (15) : 6825 - 6834
  • [28] Crystal structure of RhoA-GDP and its functional implications
    Wei, YY
    Zhang, Y
    Derewenda, U
    Liu, XP
    Minor, W
    Nakamoto, RK
    Somlyo, AV
    Somlyo, AP
    Derewenda, ZS
    [J]. NATURE STRUCTURAL BIOLOGY, 1997, 4 (09) : 699 - 703
  • [29] Sulfated polysaccharides extracted from sea algae as potential antiviral drugs
    Witvrouw, M
    DeClercq, E
    [J]. GENERAL PHARMACOLOGY-THE VASCULAR SYSTEM, 1997, 29 (04): : 497 - 511
  • [30] Structural characterization of the human respiratory syncytial virus fusion protein core
    Zhao, X
    Singh, M
    Malashkevich, VN
    Kim, PS
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (26) : 14172 - 14177